Clinical Trial

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

Study acronym: IP2-ATLANTA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-11-30; most recent amendment 2025-02-05.
Status change: Recruiting → Active, Not Recruiting 2025-02-05
Status change: Not Yet Recruiting → Recruiting 2019-07-22
Trial Details
NCT Number NCT03763253
Lead Sponsor Imperial College London
Collaborators: Wellcome Trust
Conditions Prostate Cancer, Metastatic Prostate Cancer
Enrollment 433 participants
Start Date 2019-04-10
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-07